Compare PLYM & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLYM | EVO |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.0M | 1.1B |
| IPO Year | 2017 | 2021 |
| Metric | PLYM | EVO |
|---|---|---|
| Price | $21.88 | $2.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $21.14 | $7.00 |
| AVG Volume (30 Days) | ★ 1.9M | 107.8K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | ★ 11196.82 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | $163,681,000.00 | ★ $887,396,457.00 |
| Revenue This Year | $1.88 | N/A |
| Revenue Next Year | $9.24 | $8.80 |
| P/E Ratio | $10.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.70 | $2.84 |
| 52 Week High | $22.74 | $5.10 |
| Indicator | PLYM | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 46.94 | 40.01 |
| Support Level | $21.77 | $2.86 |
| Resistance Level | $21.90 | $3.09 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 12.37 | 24.49 |
Plymouth Industrial REIT Inc is a full-service, vertically integrated, self-administered, and self-managed Maryland corporation. It is focused on the acquisition, ownership, and management of single and multi-tenant Class B industrial properties, including distribution centers, warehouses, and light industrial properties, located in secondary and primary markets across the United States. The company has one reportable segment, which is Industrial properties. The majority of its property portfolio is spread across Florida, Ohio, Indiana, Tennessee, Illinois and Georgia, among others. It receives income from the rental revenue through its properties.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.